Literature DB >> 12220420

Endoluminal methods of treating gastroesophageal reflux disease.

A Roy-Shapira1, H J Stein, Doron Scwartz, A Fich, E Sonnenschein.   

Abstract

Several endoluminal methods of treating gastroesophageal reflux disease (GERD) have either been approved, or are under investigation and development. This review outlines the two approved methods (Bard's endoluminal sewing machine and Curon's Stretta radiofrequency treatment), and describes the available data on new methods under investigation. The various methods can be divided into three broad categories: methods that create a controlled stricture, methods that bulk the gastroesophageal junction, and methods that attempt to create a fundoplication. The pros and cons of each method are discussed. Unlike medical treatment, these methods attack the reflux itself, not just the symptoms. This is a promising approach. However, the controlled stricture and bulking methods do not approach the success rate of a standard fundoplication.

Entities:  

Mesh:

Year:  2002        PMID: 12220420     DOI: 10.1046/j.1442-2050.2002.00242.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  3 in total

Review 1.  Therapeutic upper gastrointestinal tract endoscopy in Paediatric Gastroenterology.

Authors:  Imdadur Rahman; Praful Patel; Philip Boger; Shahnawaz Rasheed; Mike Thomson; Nadeem Ahmad Afzal
Journal:  World J Gastrointest Endosc       Date:  2015-03-16

2.  Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux disease.

Authors:  Werner K H Kauer; Aviel Roy-Shapira; David Watson; Menashe Sonnenschein; Elazar Sonnenschein; J Unger; M Voget; Hubert J Stein
Journal:  Surg Endosc       Date:  2009-04-09       Impact factor: 4.584

3.  Trans-oral anterior fundoplication: 5-year follow-up of pilot study.

Authors:  Aviel Roy-Shapira; Amol Bapaye; Suhas Date; Rajendra Pujari; Shivangi Dorwat
Journal:  Surg Endosc       Date:  2015-03-18       Impact factor: 4.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.